The department of Dermatology, Venereology and Leprology and Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (pgimer.edu.in) organized the conference "Dermatophytosis: Fighting the Challenge" on 2 nd and 3 rd September 2017. (Figure 1a c) -The conference was attended by about 250 delegates from all over India. It was the first conference of its kind that was dedicated to dermatophytosis, and eminent speakers from all over India deliberated on various issues and problems which are currently being faced by clinicians in the management of dermatophytosis (tinea). The conference started with a workshop on conventional and current techniques in the diagnosis of dermatophytosis/ superficial fungal infections and antifungal drug susceptibility (AFS) testing in tinea. The highlights and salient points of different lectures and presentations are presented in this paper.
Session I: Fungal pathogens, immunopathogenesis, and drug susceptibility
Dr. Shivaprakash MR started the first session with his talk on "Advances in laboratory diagnosis of dermatophytosis and PGI experience of antifungal drug susceptibility patterns in recalcitrant dermatophytosis." Following topics were covered during his talk: on epithelial cells by inducing the production of chemokines (CXCL8, CXCL1, CXCL2, and CXCL5) and antimicrobial peptides (HBD-2, LL-37, S100A7, S100A8, S100A9, β-defensins, and histatins): direct anti-fungal effects. The controversies and management dilemmas in cases of chronic and recurrent dermatophytosis were discussed in two debate sessions. Topics for "Short Debates" were carefully selected and eminent speakers and moderators participated in these brainstorming sessions and shared their experiences. A brief summary of presentations and expert comments of the first debate session moderated by Dr Abir Saraswat which discussed the epidemiology and clinical features of recalcitrant/resistant dermatophytosis are given below:
Session II: Plenary session: Recurrent/recalcitrant dermatophytosis

What do you label this emerging scenario of tinea in India -Recalcitrant or Resistant dermatophytosis?
Dr. Kabir Sardana (for recalcitrant tinea) and Dr Mukesh Girdhar (for resistant tinea) Consensus: multifactorial causation is present but the resistance in fungal species is present and is a major threat.
Should we give blanket treatment to all family members/contacts in cases of recurrent/chronic tinea?
Dr. P Narsimha Rao (blanket treatment in all recalcitrant tinea) and Dr. Sandipan Dhar (against).
For:
Ping pong effect is significant
Children being infected by their parents
Sharing of clothes is present Asymptomatic carriers and fomite transmission is present and responsible for the persistence of tinea in the house despite clinical clearance and they present with relapse very early Consensus: both resistance and recalcitrance may be contributing to the current scenario.
Is fungal culture and antifungal drug susceptibility test indicated in all cases of recalcitrant tinea?
Dr. Shukla Das (for fungal culture and AFS studies in all recalcitrant tinea) and Dr. Davinder Parsad (against).
For
Need to identify the organism to detect any exotic organism, to find out the most common organism, and to avoid misdiagnosis and mistreatment 
Do you think that topical corticosteroid abuse is the major reason for the current scenario of recalcitrant dermatophytosis?
Dr. Rajeev Sharma (steroid abuse is major reason for recalcitrant tinea) and Dr Vikram Mahajan (against). Consensus: blanket treatment not required, treat all symptomatic cases.
Session III: Plenary session: Chronic dermatophyte infections
Dr. Ruth Ashbey, Visiting Lecturer, School of Molecular and Cellular Biology, University of Leeds, UK presented second keynote lecture of conference. "Antifungal aspects of dermatophytosis -the same old, same mould." The highlights of her talk were. She also reiterated that we should define the clinical breakpoints of antifungal resistance in addition to the mycological breakpoints, which need further refinement.
Antifungal resistance in Dermatophytes
The fungal forms isolated from the skin are arthrospores which are inherently less susceptible to the antifungals and this form is not tested in the mycological AST. 
Session V: Therapeutics 2
Dr. Sandipan Dhar delivered a lecture on the management of dermatophytosis in patients with concomitant systemic diseases and dermatoses • Special challenges in the management of dermatophytosis are dermatoses predisposing to recurrent infections, systemic illness that may cause immunosuppression, topical and systemic drugs that may depress CMI locally or systemically, associated hepatic and renal dysfunction may affect choice and dose of drugs and possibility of drug interaction due to continuing concurrent medications • Barrier impairment essential for the establishment and perpetuation of infection, Dermatoses with barrier defect such as atopic dermatitis (AD) or psoriasis predispose to recalcitrant and rapidly spreading infections and the success of treatment outcome will depend on barrier repair and control of pruritus besides adequate antifungal treatment • Talked about the need for modified treatment protocols (higher dose and longer duration) in patients with comorbid conditions (such as lymphomas, diabetes, vitiligo, psoriasis, or AD patients on immunosuppression and those on polypharmacy) • He stressed that the treatment of dermatophytosis in these conditions should be at the discretion of the treating dermatologist taking into consideration the adverse effects of the various drugs as well as the laboratory investigations of the patients being treated, and we should aim for both mycological and clinical cure.
Dr. Arun Inamadar deliberated on the important and tricky issue of managing dermatophytosis in pregnancy and children. Antifungal prescription remains a challenge in pregnant women because of uncertainties regarding fetal toxicity and altered maternal pharmacokinetic parameters which may affect efficacy or increase maternal and fetal toxicity.
• Better to treat all cases of dermatophytosis in pregnant women with topical antifungals (terbinafine and azoles), if possible, as they are safe in all stages of pregnancy • Animal and human data provide evidence that azoles could be teratogenic and oral terbinafine is pregnancy category B and can be used safely after 1 st trimester in extensive cases taking into account other comorbidities and potential drug interactions • Fluconazole >300 mg is pregnancy category C and should not be given • Fluconazole ≤300 mg is category B and can be tried after 1 st trimester • Need to have effective contraception for 2 months after taking oral itraconazole before the female can plan pregnancy • Topical antifungals are the first choice when we have to treat children with dermatophytosis, however, most topical azoles are fungistatic and probably require intact local immunity for the eradication of dermatophytes • Among the systemic antifungals terbinafine and itraconazole are the preferred agents at doses of 5 mg/kg/day • Treatment duration varies with indication, with most studies using 2-4 weeks of therapy in children with tinea capitis or tinea corporis and 6-12 weeks of therapy in children with onychomycosis • Oral terbinafine is associated with rare but serious adverse effects (e.g., blood dyscrasias, liver failure), hence if >6 weeks of terbinafine tablets are required, monitor blood count and liver enzymes. • The US FDA found that skin reactions were the most often reported post-marketing adverse event for terbinafine for children. The second debate on day 2 was the most awaited session as it discussed the dilemma that all dermatologists face everyday while managing dermatophytosis in their routine practice. The session was moderated by Dr. Binod Khaitan.
Is there any relevance of pk/pd studies in management of recalcitrant tinea?
Dr. Kabir Sardana (pk/pd studies are relevant in recalcitrant tinea) and Dr. Nusrat Shafique (against).
For:
Pk-pd studies are the basis on which we prescribe drugs for tinea, and studies have demonstrated that:
Terbinafine and itraconazole concentrates in stratum corneum much more than in serum and remains for a long period of time.
Pk and pd of antifungals in skin and in serum are different.
Drug interactions can be predicted based on these studies
Against:
The studies are still in their nascent stages and do not consider characteristics of skin of different patients into account and do not consider the various comorbid conditions that the patient is having, no minute-to-minute change in drug concentration considered, environmental effects not considered in any of the studies so far.
Consensus -It is a good start but a long way to go till these studies achieve relevance in dermatophytosis. Consensus -Terbinafine can be updosed till 250 mg BD and itraconazole till 100 mg BD; no role in updosing any further in tinea until there is concrete evidence of justifying higher/double dosage of antifungals as all these systemic agents are associated with serious adverse effects also.
Role of updosing antifungal treatment beyond standard recommendation?
Role of longer duration of antifungal treatment beyond standard recommendation?
Dr. Lalit Gupta (for longer duration to treat dermatophytosis) and Dr. Rashmi Sarkar (against).
Steroids used by a majority of patients for self-treatment of their tinea leads to a decrease in local immunity which takes about 4 weeks to restore, therefore, longer duration of therapy is better Duration of 1-2 weeks for systemic antifungals as is given in a majority of standard textbooks is grossly inadequate as far as real-world scenario goes 
Role of combination of systemic antifungals in recalcitrant tinea cases?
Dr. Akanksha (for role of combination antifungals in recalcitrant tinea) and Dr. Rajiv Sharma (against)
The current situation of dermatophytosis in India may give rise to a scenario where multidrug therapy (MDT) will be needed to combat dermatophytosis just like leprosy and tuberculosis Development of resistance will be offset with combinations and the time required to treat may become less Combination of antifungals are already indicated in other fungal infections such as invasive aspergillosis, cryptococcal meningitis, etc.
Terbinafine and azoles can be combined in tinea because they act on sequential steps in ergosterol synthesis and the efficacy will be better Sequential and parallel therapy can be planned with terbinafine and azoles to minimize the chances of resistance and adverse effects of the drugs since less dose will be required to treat.
Combinations will increase the adverse effects that the patient will be facing because of the drugs.
Topical and systemic therapy can be combined but to combine terbinafine and azoles systemically, which both act on the same pathway is not a good rationale and both are also metabolized by the liver.
Griseofulvin should not be combined with azoles or terbinafine as well for similar reasons.
Consensus -Sequential therapy can be tried in cases of difficult to treat tinea, however, parallel therapy will definitely increase the adverse effects, and hence, should not be tried.
Role of retinoids in the management of chronic/ recurrent dermatophytosis?
Dr. Rahul Mahajan (for use of retinoids in chronic dermatophytosis) and Dr. Garima (against)
Retinoids increase the expression of innate immunity associated markers such as TLRs, hBD so can be tried.
They also break down the biofilms formed by tinea, and hence can be tried.
There are studies which support tazarotene use in onychomycosis and isotretinoin in combination with itraconzole in tinea.
Against:
Retinoids increase turnover of stratum corneum, hence, the reservoir effect of terbinafine and itraconazole is lost.
Retinoids also decrease sebum production, hence the excretion of drugs which use sebum is lost eg: Itraconazole
Retinoids skew the Th1 to Th2-mediated immune pathways and Th2 pathway promotes recalcitrant dermatophytosis.
Very little is known about the mechanism of action of retinoids, and much remains unknown; therefore, the combination with systemic antifungals or as a standalone therapy is not recommended as of now
Consensus -Not recommended as of now; more studies are needed.
The sessions were helpful in answering some queries related to the diagnosis and management of dermatophytosis and generated new ideas for future research as well. It was a good forum where different experts from specialities such as dermatology, microbiology, pathology, and pharmacology came together and presented their views and opinions in tackling the problem of recalcitrant or recurrent dermatophytosis. The current scenario calls for a multispeciality approach in tackling the menace of dermatophyte infections of skin.
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